The recently published PROMISE-PET study, a multicenter retrospective analysis including 2414 patients with PCa, aimed to assess the prognostic value of PSMA-PET using PROMISE criteria, demonstrating its potential as a novel biomarker for overall survival in prostate cancer across all stages. Here, FOLH1 is linked to posterior cortical atrophy.